- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04348071
Safety and Efficacy of Ruxolitinib for COVID-19
This study plans to learn more about the effects of a medicine called ruxolitinib on the progression of COVID-19 (coronavirus disease of 2019), the medical condition caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Ruxolitinib is FDA-approved for the treatment of myelofibrosis, polycythemia vera, and graft-versus-host disease. This study intends to define the impact of ruxolitinib on the severity and progression of COVID-19. This drug might to lower the hyperinflammation caused by the virus, which would prevent damage to the lungs and possibly other organs.
The study will recruit patients who have been diagnosed with COVID-19.
The goal is to recruit 80 patients.
Study Overview
Detailed Description
Study Type
Phase
- Phase 2
- Phase 3
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female aged 18 - 89 years at time of enrollment
- Hospitalized (or documented plan to hospitalize if patient is in the emergency department) with symptoms suggestive of COVID-19
- lllness of any duration that meets each of the following:
- Evidence of pneumonia, including radiographic infiltrates by imaging (chest x-ray, CT scan, etc.) or clinical assessment (rales/crackles on exam)
- Requires supportive care, including non-invasive supplemental oxygen
- Laboratory-confirmed SARS-CoV-2 infection as determined by PCR or other commercial or public health assay within 7 days of enrollment
- Understands and agrees to comply with planned study procedures
- Provides informed consent signed by study patient or legally acceptable representative
Exclusion Criteria:
- Absolute platelet counts are less than 75 x 10^9/L
- Absolute neutrophil count is less than 0.5 x 10^9/L
- Hemoglobin is less than 8 g/dL
- Severe renal impairment defined by serum creatinine greater than 2 mg/dL or CrCl less than 30 mL/min
- Treatment with other JAK inhibitors, strong CYP3A4 inhibitors, biologic disease-modifying anti-rheumatic drugs (DMARDs, including anti-IL-6 or anti-IL-6R antibodies), or potent immunosuppressants such as azathioprine and cyclosporine concurrently or within the past 5 days. Note: recent or concurrent treatment with hydroxychloroquine or chloroquine is allowable, as these are 'non-biologic' DMARDs with potential antiviral activity.
- History of HIV infection and on active immunosuppressant therapy
- Current hematological or solid organ malignancy and on active immunosuppressant therapy
- Active tuberculosis (TB) infection or known or suspected systemic bacterial or fungal infection
- Pregnancy or breast feeding
- Known allergy to ruxolitinib
- In the opinion of the investigator, they are unlikely to survive for >48 hours from screening
- Any physical examination findings and/or history of any illness that, in the opinion of the investigator, might confound the results of the study or pose an additional risk to the patient by their participation in the study
Additional Exclusion Criteria for Phase 2 only:
- Invasive oxygen supplementation, including mechanical ventilation and extracorporeal membrane oxygenation (ECMO)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Ruxolitinib
This study is an Adaptive Phase 2/3 trial designed to test the safety (Phase 2) and efficacy (Phase 2 and 3) of ruxolitinib to treat COVID-19.
Phase 2 consists of a single-arm, open-label assignment of 20 participants receiving 10 mg ruxolitinib twice daily for 14 days.
Phase 3 consists of a single-arm, open-label assignment of 60 additional participants receiving ruxolitinib at the same dose.
In both phases, participants will be monitored daily while hospitalized for 29 days, or until discharge, whichever occurs first.
Participants who are discharged will be followed up with via phone on Day 15 and Day 29.
|
Participants will receive 10 mg ruxolitinib twice daily.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Phase 2: Cumulative incidence of Grade 3 and 4 adverse events (AEs)
Time Frame: Day 0 (screening) through Day 29
|
Grade 3 AEs are defined as events that interrupt usual activities of daily living, or significantly affects clinical status, or may require intensive therapeutic intervention.
Severe events are usually incapacitating.
Grade 4 AEs are defined as events that are potentially life threatening.
AEs will be collected and graded daily and cumulative incidence will be reported.
|
Day 0 (screening) through Day 29
|
Phase 2: Cumulative incidence of serious adverse events (SAEs)
Time Frame: Day 0 (screening) through Day 29
|
An SAE is defined as an AE that is life-threatening or results in death, inpatient hospitalization or prolongation of existing hospitalization, a persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions, or a congenital anomaly/birth defect.
SAEs will be collected and graded daily and cumulative incidence will be reported.
|
Day 0 (screening) through Day 29
|
Phase 2: Changes in white blood cell count (CBC) through Day 15
Time Frame: Day 1 to Day 15
|
Safety assessment via standard blood chemistry and metabolic panels will be performed daily as recommended by participant's physician as standard of care (SOC).
Mean changes from baseline to Day 15 will be reported.
|
Day 1 to Day 15
|
Phase 2: Changes in hemoglobin through Day 15
Time Frame: Day 1 to Day 15
|
Day 1 to Day 15
|
|
Phase 2: Changes in platelets through Day 15
Time Frame: Day 1 to Day 15
|
Day 1 to Day 15
|
|
Phase 2: Changes in creatinine through Day 15
Time Frame: Day 1 to Day 15
|
Day 1 to Day 15
|
|
Phase 2: Changes in glucose through Day 15
Time Frame: Day 1 to Day 15
|
Day 1 to Day 15
|
|
Phase 2: Changes in prothrombin time (PT) through Day 15
Time Frame: Day 1 to Day 15
|
Day 1 to Day 15
|
|
Phase 2: Changes in total bilirubin through Day 15
Time Frame: Day 1 to Day 15
|
Day 1 to Day 15
|
|
Phase 2: Changes in ALT through Day 15
Time Frame: Day 1 to Day 15
|
Day 1 to Day 15
|
|
Phase 2: Changes in AST through Day 15
Time Frame: Day 1 to Day 15
|
Day 1 to Day 15
|
|
Phase 2: Changes in white blood cell count (CBC) through End of Study (EOS)
Time Frame: Day through Day 29 or hospital discharge, whichever is first
|
Safety assessment via standard blood chemistry and metabolic panels will be performed daily as recommended by participant's physician as SOC.
Mean changes from baseline to EOS will be reported.
|
Day through Day 29 or hospital discharge, whichever is first
|
Phase 2: Changes in hemoglobin through End of Study (EOS)
Time Frame: Day 1 through Day 29 or hospital discharge, whichever is first
|
Day 1 through Day 29 or hospital discharge, whichever is first
|
|
Phase 2: Changes in platelets through End of Study (EOS)
Time Frame: Day 1 through Day 29 or hospital discharge, whichever is first
|
Day 1 through Day 29 or hospital discharge, whichever is first
|
|
Phase 2: Changes in creatinine through End of Study (EOS)
Time Frame: Day 1 through Day 29 or hospital discharge, whichever is first
|
Day 1 through Day 29 or hospital discharge, whichever is first
|
|
Phase 2: Changes in glucose through End of Study (EOS)
Time Frame: Day 1 through Day 29 or hospital discharge, whichever is first
|
Day 1 through Day 29 or hospital discharge, whichever is first
|
|
Phase 2: Changes in prothrombin time (PT) though End of Study (EOS)
Time Frame: Day 1 through Day 29 or hospital discharge, whichever is first
|
Day 1 through Day 29 or hospital discharge, whichever is first
|
|
Phase 2: Changes in total bilirubin through End of Study (EOS)
Time Frame: Day 1 through Day 29 or hospital discharge, whichever is first
|
Day 1 through Day 29 or hospital discharge, whichever is first
|
|
Phase 2: Changes in ALT through End of Study (EOS)
Time Frame: Day 1 through Day 29 or hospital discharge, whichever is first
|
Day 1 through Day 29 or hospital discharge, whichever is first
|
|
Phase 2: Changes in AST through End of Study (EOS)
Time Frame: Day 1 through Day 29 or hospital discharge, whichever is first
|
Day 1 through Day 29 or hospital discharge, whichever is first
|
|
Phase 3: Percentage of patients reporting each severity on an 8-point ordinal scale at Day 15
Time Frame: Day 15
|
The 8-point ordinal scale described below, where a lower score indicates a worse outcome, will be performed daily or as recommended by participant's physician as SOC. The percent of participants scored at each severity will be reported on Day 15. The 8-point ordinal scale is as follows:
|
Day 15
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Phase 2: Change in the 8-point ordinal scale
Time Frame: Day 1 to Day 29
|
Day 1 to Day 29
|
|
Phase 2: Change in National Early Warning Score (NEWS)
Time Frame: Day 1 through Day 29 or hospital discharge, whichever is first
|
Day 1 through Day 29 or hospital discharge, whichever is first
|
|
Phase 3: Change in the 8-point ordinal scale
Time Frame: Day 1 to Day 29
|
Day 1 to Day 29
|
|
Phase 3: Change in National Early Warning Score (NEWS)
Time Frame: Day 1 to Day 29 or hospital discharge, whichever is first
|
Day 1 to Day 29 or hospital discharge, whichever is first
|
|
Phase 3: Time to an improvement of one category using the 8-point ordinal scale
Time Frame: Day 1 to Day 29 or hospital discharge, whichever is first
|
Day 1 to Day 29 or hospital discharge, whichever is first
|
|
Phase 3: Time to an improvement of two categories using the 8-point ordinal scale
Time Frame: Day 1 to Day 29 or hospital discharge, whichever is first
|
Day 1 to Day 29 or hospital discharge, whichever is first
|
|
Phase 3: Time to discharge or to a NEWS ≤2 and maintained for 24 hours, whichever occurs first
Time Frame: Day 1 through Day 29 or hospital discharge, whichever is first
|
Day 1 through Day 29 or hospital discharge, whichever is first
|
|
Phase 3: Cumulative incidence of Grade 3 and 4 adverse events (AEs)
Time Frame: Day 0 (screening) through Day 29
|
Day 0 (screening) through Day 29
|
|
Phase 3: Cumulative incidence of serious adverse events (SAEs)
Time Frame: Day 0 (screening) through Day 29
|
Day 0 (screening) through Day 29
|
|
Phase 3: Duration of hospitalization
Time Frame: Day 1 through Day 29 or hospital discharge, whichever is first
|
Day 1 through Day 29 or hospital discharge, whichever is first
|
|
Phase 3: Duration of new oxygen use
Time Frame: Day 1 through Day 29 or hospital discharge, whichever is first
|
Day 1 through Day 29 or hospital discharge, whichever is first
|
|
Phase 3: Duration of new ventilator or ECMO use
Time Frame: Day 1 to Day 29 or hospital discharge, whichever is first
|
Day 1 to Day 29 or hospital discharge, whichever is first
|
|
Phase 3: Incidence of discontinuation or temporary suspension of drug for any reason
Time Frame: Day 1 through Day 29 or hospital discharge, whichever is first
|
Day 1 through Day 29 or hospital discharge, whichever is first
|
|
Phase 3: Incidence of new oxygen use
Time Frame: Day 1 to Day 29 or hospital discharge, whichever is first
|
Day 1 to Day 29 or hospital discharge, whichever is first
|
|
Phase 3: Incidence of new ventilator use
Time Frame: Day 1 to Day 29 or hospital discharge, whichever is first
|
Day 1 to Day 29 or hospital discharge, whichever is first
|
|
Phase 3: Number of oxygen free days
Time Frame: Day 1 through Day 29 or hospital discharge, whichever is first
|
Day 1 through Day 29 or hospital discharge, whichever is first
|
|
Phase 3: Number of ventilator or ECMO free days
Time Frame: Day 1 through Day 29 or hospital discharge, whichever is first
|
Day 1 through Day 29 or hospital discharge, whichever is first
|
|
Phase 3: 14 day mortality rate
Time Frame: Day 1 through Day 15
|
Day 1 through Day 15
|
|
Phase 3: 28 day mortality rate
Time Frame: Day 1 through Day 29
|
Day 1 through Day 29
|
|
Phase 3: Changes in white blood cell count (CBC) through Day 15
Time Frame: Day 1 to Day 15
|
Day 1 to Day 15
|
|
Phase 3: Changes in hemoglobin through Day 15
Time Frame: Day 1 to Day 15
|
Day 1 to Day 15
|
|
Phase 3: Changes in platelets through Day 15
Time Frame: Day 1 to Day 15
|
Day 1 to Day 15
|
|
Phase 3: Changes in creatinine through Day 15
Time Frame: Day 1 to Day 15
|
Day 1 to Day 15
|
|
Phase 3: Changes in glucose through Day 15
Time Frame: Day 1 to Day 15
|
Day 1 to Day 15
|
|
Phase 3: Changes in prothrombin time (PT) through Day 15
Time Frame: Day 1 to Day 15
|
Day 1 to Day 15
|
|
Phase 3: Changes in total bilirubin through Day 15
Time Frame: Day 1 to Day 15
|
Day 1 to Day 15
|
|
Phase 3: Changes in ALT through Day 15
Time Frame: Day 1 to Day 15
|
Day 1 to Day 15
|
|
Phase 3: Changes in AST through Day 15
Time Frame: Day 1 to Day 15
|
Day 1 to Day 15
|
|
Phase 3: Changes in white blood cell count (CBC) through End of Study (EOS)
Time Frame: Day 1 through Day 29 or hospital discharge, whichever is first
|
Safety assessment via standard blood chemistry and metabolic panels will be performed daily as recommended by participant's physician as SOC.
Mean changes from baseline to EOS will be reported.
|
Day 1 through Day 29 or hospital discharge, whichever is first
|
Phase 3: Changes in hemoglobin through End of Study (EOS)
Time Frame: Day 1 through Day 29 or hospital discharge, whichever is first
|
Day 1 through Day 29 or hospital discharge, whichever is first
|
|
Phase 3: Changes in platelets through End of Study (EOS)
Time Frame: Day 1 through Day 29 or hospital discharge, whichever is first
|
Day 1 through Day 29 or hospital discharge, whichever is first
|
|
Phase 3: Changes in creatinine through End of Study (EOS)
Time Frame: Day 1 through Day 29 or hospital discharge, whichever is first
|
Day 1 through Day 29 or hospital discharge, whichever is first
|
|
Phase 3: Changes in glucose through End of Study (EOS)
Time Frame: Day 1 through Day 29 or hospital discharge, whichever is first
|
Day 1 through Day 29 or hospital discharge, whichever is first
|
|
Phase 3: Changes in prothrombin time (PT) though End of Study (EOS)
Time Frame: Day 1 through Day 29 or hospital discharge, whichever is first
|
Day 1 through Day 29 or hospital discharge, whichever is first
|
|
Phase 3: Changes in total bilirubin through End of Study (EOS)
Time Frame: Day 1 through Day 29 or hospital discharge, whichever is first
|
Day 1 through Day 29 or hospital discharge, whichever is first
|
|
Phase 3: Changes in ALT through End of Study (EOS)
Time Frame: Day 1 through Day 29 or hospital discharge, whichever is first
|
Day 1 through Day 29 or hospital discharge, whichever is first
|
|
Phase 3: Changes in AST through End of Study (EOS)
Time Frame: Day 1 through Day 29 or hospital discharge, whichever is first
|
Day 1 through Day 29 or hospital discharge, whichever is first
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 20-0869
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- Study Protocol
- Statistical Analysis Plan (SAP)
- Clinical Study Report (CSR)
- Analytic Code
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on COVID-19
-
University of Roma La SapienzaQueen Mary University of London; Università degli studi di Roma Foro Italico; Bios Prevention SrlCompletedPost Acute Sequelae of COVID-19 | Post COVID-19 Condition | Long-COVID | Chronic COVID-19 SyndromeItaly
-
Yang I. PachankisActive, not recruitingCOVID-19 Respiratory Infection | COVID-19 Stress Syndrome | COVID-19 Vaccine Adverse Reaction | COVID-19-Associated Thromboembolism | COVID-19 Post-Intensive Care Syndrome | COVID-19-Associated StrokeChina
-
Massachusetts General HospitalRecruitingPost Acute COVID-19 Syndrome | Long COVID | Post Acute Sequelae of COVID-19 | Long COVID-19United States
-
Indonesia UniversityRecruitingPost-COVID-19 Syndrome | Long COVID | Post COVID-19 Condition | Post-COVID Syndrome | Long COVID-19Indonesia
-
Erasmus Medical CenterDa Vinci Clinic; HGC RijswijkNot yet recruitingPost-COVID-19 Syndrome | Long COVID | Long Covid19 | Post COVID-19 Condition | Post-COVID Syndrome | Post COVID-19 Condition, Unspecified | Post-COVID ConditionNetherlands
-
Dr. Soetomo General HospitalIndonesia-MoH; Universitas Airlangga; Biotis Pharmaceuticals, IndonesiaRecruitingCOVID-19 Pandemic | COVID-19 Vaccines | COVID-19 Virus DiseaseIndonesia
-
University of Witten/HerdeckeInstitut für Rehabilitationsforschung NorderneyCompletedPost-COVID-19 Syndrome | Long-COVID-19 SyndromeGermany
-
Jonathann Kuo, MDActive, not recruitingSARS-CoV2 Infection | Post-COVID-19 Syndrome | Dysautonomia | Post Acute COVID-19 Syndrome | Long COVID | Long Covid19 | COVID-19 Recurrent | Post-Acute COVID-19 | Post-Acute COVID-19 Infection | Post Acute Sequelae of COVID-19 | Dysautonomia Like Disorder | Dysautonomia Orthostatic Hypotension Syndrome | Post... and other conditionsUnited States
-
University Hospital, Ioannina1st Division of Internal Medicine, University Hospital of IoanninaRecruitingCOVID-19 Pneumonia | COVID-19 Respiratory Infection | COVID-19 Pandemic | COVID-19 Acute Respiratory Distress Syndrome | COVID-19-Associated Pneumonia | COVID 19 Associated Coagulopathy | COVID-19 (Coronavirus Disease 2019) | COVID-19-Associated ThromboembolismGreece
Clinical Trials on Ruxolitinib
-
First Affiliated Hospital of Zhejiang UniversityXiangya Hospital of Central South University; Second Affiliated Hospital, School... and other collaboratorsRecruitingHematologic Malignancy | Bronchiolitis Obliterans SyndromeChina
-
Novartis PharmaceuticalsTerminatedMyelofibrosis With High Molecular Risk MutationsBelgium, Spain, United Kingdom, Hungary, Italy, Japan, Taiwan, Germany, Canada, Singapore, Austria, Australia, France, Israel, Sweden, Switzerland, Hong Kong, Greece, Turkey, Brazil, Russian Federation, Denmark, Portugal, Norway, Poland
-
Incyte CorporationActive, not recruiting
-
Julie NangiaIncyte Corporation; Translational Breast Cancer Research ConsortiumRecruitingDuctal Carcinoma In Situ | Atypical Ductal Hyperplasia | Atypical Lobular Hyperplasia | Lobular Carcinoma In SituUnited States
-
University of ZurichIncyte CorporationNot yet recruitingExanthema | Lichenoid Skin Rashes Under Anti-PD1 Tumor Therapy
-
Beijing Friendship HospitalUnknownHemophagocytic LymphohistiocytosisChina
-
Children's Hospital Medical Center, CincinnatiRecruitingBronchiolitis Obliterans (BO) | Hematopoietic Stem Cell Transplant (HSCT)United States
-
University of JenaCompleted
-
University of Michigan Rogel Cancer CenterCompletedHemophagocytic Syndrome (HPS)United States
-
Margherita MaffioliUnknown